Corporate ActionJul 31, 2026, 06:08 AM
Moleculin Biotech to Raise $9.1M via Stock & Warrants Offering
AI Summary
Moleculin Biotech, Inc. is conducting a "reasonable best efforts" public offering to raise approximately $9.1 million in net proceeds. The offering includes up to 4,566,210 shares of common stock, up to 4,566,210 pre-funded warrants, and up to 13,698,630 common warrants, with an assumed combined price of $2.19 per share. Proceeds will fund clinical development of Annamycin, including the pivotal Phase 2/3 MIRACLE trial for R/R AML, which recently reported positive interim efficacy results. The company will require significant additional financing beyond this offering.
Key Highlights
- Public offering of up to 4,566,210 common shares and 13,698,630 common warrants.
- Offering also includes up to 4,566,210 pre-funded warrants.
- Assumed combined public offering price of $2.19 per share and common warrants.
- Estimated net proceeds of approximately $9.1 million after fees.
- Proceeds to fund Annamycin clinical development and working capital.
- Interim MIRACLE trial results: CR rates of 43% and 36% in Annamycin arms vs. 12% in control.
- Interim MIRACLE trial results: CRc rates of 50% and 57% in Annamycin arms vs. 29% in control.
- Common warrants require stockholder approval to be exercisable; otherwise, they have no value.
Price Impact
More from MBRX